Indian Journal of Pathology and Oncology


Her2neu expression in urinary bladder cancer: Histopathological, clinico-radiological and epidemiological aspects


Full Text PDF Share on Facebook Share on Twitter


Article Type : Research Article

Author Details: Mahak Agarwal,Milan Jaiswal*,Surabhi Pandey,Rehan Fareed

Volume : 6

Issue : 3

Online ISSN : 2394-6792

Print ISSN : 2394-6784

Article First Page : 489

Article End Page : 496


Abstract

Objectives: Her2/neu in bladder carcinomas as a prognostic marker has been widely studied, but with variable results. The potential for development of anti Her2/neu targeted therapy in Her2/neu positive tumours, warrants the need for a definitive conclusion on the Her2/neu status. Therefore, this study is undertaken to evaluate possible correlation between Her2/neu expression and various epidemiological, clinico-radiological and histological variables.
Materials and Methods: This prospective study was performed in the Pathology department, on 43 patients with bladder malignancies, diagnosed clinically in the Surgery Department at a tertiary care medical institute of Rohilkhand region. Formalin fixed TURBT specimens were processed as per protocol. Hematoxylin and Eosin stained sections were observed microscopically along with immunohistochemistry for Her2/neu, by three independent observers. ?2 test with Yates correction was applied to evaluate possible association of Her2/neu with various variables. P value of <0>
Results: Her2/neu positivity was seen in 41.86% of the cases.Her2/neu expression was found to be statistically significant with respect to histological grade (p = 0.026) and pathological stage (p=0.025). Statistically insignificant results were obtained for Her2/neu expression with respect to patient age, gender, history of smoking, presenting complaints and ultrasonographic findings.
Conclusion: A positive association between Her2/neu expression and tumour grade and stage suggests that Her2/neu status maybe helpful in formulating the treatment plan for patients of urothelial carcinoma. However, further studies with larger sample size and correlating Her2/neu expression with the patient survival are needed to developanti Her2/neu targeted therapy.

Keywords: Bladder cancer, ErbB2, Her2/neu, Immunohistochemistry, Urothelial carcinoma.

Doi :-https://doi.org/10.18231/j.ijpo.2019.094